Citigroup Inc Insmed Inc Call Options Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 12, 2024	SELL	$22.0 - $69.71 $2.87 Million - $9.1 Million	-130,600 Reduced 83.93%	25,000 $1.68 Million
Q1 2024 May 10, 2024	BUY	$25.72 - $29.94 $2.59 Million - $3.01 Million	100,600 Added 182.91%	155,600 $4.22 Million
Q4 2023 Feb 09, 2024	BUY	$23.42 - $31.74 $1.29 Million - $1.75 Million	55,000 New	55,000 $1.7 Million
Q1 2023 May 11, 2023	BUY	$16.26 - $21.73 $81,300 - $108,650	5,000 Added 20.16%	29,800 $508,000
Q4 2022 Feb 09, 2023	BUY	$16.98 - $23.15 $421,104 - $574,120	24,800 New	24,800 $495,000

467

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.